Compare · CAH vs MEDS
CAH vs MEDS
Side-by-side comparison of Cardinal Health Inc. (CAH) and DataMeds AI Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAH and MEDS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- CAH is the larger of the two at $64.33B, about 15178.0x MEDS ($4.2M).
- CAH has been more active in the news (17 items in the past 4 weeks vs 6 for MEDS).
- CAH has more recent analyst coverage (25 ratings vs 1 for MEDS).
- Company
- Cardinal Health Inc.
- DataMeds AI Inc.
- Price
- -
- -
- Market cap
- $64.33B
- $4.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 17
- 6
- Recent ratings
- 25
- 1
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
DataMeds AI Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.
Latest CAH
- Director Hall Patricia Hemingway was granted 1,204 shares, increasing direct ownership by 4% to 29,849 units (SEC Form 4)
- Director Johri Akhil was granted 1 shares, increasing direct ownership by 0.00% to 22,869 units (SEC Form 4)
- Director Killefer Nancy was granted 755 shares, increasing direct ownership by 3% to 28,379 units (SEC Form 4)
- Director Mundkur Christine was granted 755 shares, increasing direct ownership by 10% to 8,291 units (SEC Form 4)
- Director Musslewhite Robert W was granted 755 shares, increasing direct ownership by 36% to 2,871 units (SEC Form 4)
- Director Ramakrishna Sudhakar was granted 755 shares, increasing direct ownership by 36% to 2,871 units (SEC Form 4)
- Director Edison Sheri H. was granted 755 shares, increasing direct ownership by 5% to 15,603 units (SEC Form 4)
- New insider Zielinski Anita A claimed ownership of 5,715 shares (SEC Form 3)
- Director Evans David C was granted 755 shares, increasing direct ownership by 5% to 16,128 units (SEC Form 4)
- Director Brennan Michelle was granted 755 shares, increasing direct ownership by 9% to 8,841 units (SEC Form 4)
Latest MEDS
- UPDATING ORIGINAL RELEASE DataMEDS AI Releases CEO Letter
- DataMEDS AI Releases CEO Letter
- DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
- DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
- DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
- DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- DataMeds Regains Compliance With NASDAQ Listing Standards